Paul Owren,Christopher Bjerkelund and the dawn of controlled trials in Norway

Stormorken H. The discovery of factor V: a tricky clotting factor. J Thrombosis Haemost 2003; 1: 206–213.

Stormorken H. Paul Arnor Owren. En medisinens mester [Paul Arnor Owren. A Master of Medicine]. Asker: Tell forlag, 2000.

Bächli E. History of tissue factor. Br J Haematol 2000; 110: 248–255.

Owren PA. Parahaemophilia; haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet 1947; 1: 446–444.

Owren PA. The Coagulation of Blood: Investigations on a New Clotting Factor. Oslo: JC Gundersen, 1947.

Owren PA. Long-term dicoumarol therapy in cardiovascular diseases. Acta Med Scand Suppl 1953; 287: 46–48.

Bjerkelund CJ. The effect of long-term treatment with dicoumarol in myocardial infarction. A controlled clinical study. Acta Med Scand Suppl 1957; 330: 1–212.

Müller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Med Scand 1938; 95: 75–84.

Owren PA Hellem AJ Ödegaard A. Linolenic acid for the prevention of thrombosis and myocardial infarction. Lancet 1964; 284: 975–979.

Natvig H Borchgrevink CF Dedichen J Owren PA Schiotz EH Westlund K. A controlled trial of the effect of linolenic acid on incidence of coronary heart disease. Scand J Clin Lab Investig 1968; 21: 1–20.

Strøm A Jensen RA. Mortality from circulatory diseases in Norway 1940–1945. Lancet 1951; 1: 126–129.

Life Insurance Companies’ Institute for Medical Statistics at the Oslo City Hospitals. Myocardial infarction. An epidemiological and prognostic study of patients from five departments of internal medicine in Oslo 1935–1949. Acta Med Scand 1956; 315: 1–58.

Franchini M Liumbruno GM Bonfanti C Lippi G. The evolution of anticoagulant therapy. Blood Transfusion 2016; 14: 175–184.

Timson DJ. Dicoumarol: a drug which hits at least two very different targets in vitamin K metabolism. Curr Drug Targets 2017; 18: 500–510.

Bjerkelund CJ. The method of administering dicoumarol. Lancet 1953; 1: 260–265.

Larsen Ø. Doktorskole og medisinstudium. Det medisinske fakultet ved Universitetet i Oslo gjennom 200 år (1814–2014) [Doctoral school and medical studies. The medical faculty at the University of Oslo over 200 years (1814–2014)]. Michael Suppl 2014; 15: 598.

Wright IS Marple CD Beck DR. Report of the committee for the evaluation of anticoagulants in the treatment of coronary thrombosis with myocardial infarction. Am Heart J 1948; 36: 801–815.

Corbett MS Watson J Eastwood A. Randomised trials comparing different healthcare settings: an exploratory review of the impact of pre-trial preferences on participation, and discussion of other methodological challenges. BMC Health Serv Res 2016; 16: 589.

Moodley J Naidoo S Moodley J Ramjee G. Sharing of investigational drug among participants in the voice trial. AIDS Behav 2016; 20: 2709–2714.

Cohen J. The statistical power of abnormal – social psychological research: a review. J Abnormal Soc Psychol 1962; 65: 145–153.

Descôteaux J. Statistical power: an historical introduction. Tut Quant Methods Psychol 2007; 3: 28–34.

Fagerland MW Lydersen S Laake P. Recommended confidence intervals for two independent binomial proportions. Stat Methods Med Res 2015; 42: 224–254.

Chalmers I Matthews R Glasziou P Boutron I Armitage P. Analysis of clinical trial by treatment allocated or by treatment received? Applying ‘the intention-to-treat principle’. 2023. JLL Bulletin: Commentaries on the history of treatment evaluation. See www.jameslindlibrary.org/articles/analysis-of-clinical-trial-by-treatment-allocated-or-by-treatment-received-applying-the-intention-to-treat-principle/ (last checked 15 November 2023).

Detry MA Lewis RJ. The intention-to-treat principle. How to assess the true effect of choosing a medical treatment. JAMA 2014; 312: 85–86.

Montori VM Guyatt GH. Intention-to-treat principle. CMAJ 2001; 165: 1139–1141.

Armitage P Borchgrevink CF. Prevention of recurrences of myocardial infarction. Arch Intern Med 1966; 118: 270–273.

Conrad LL Kyriakopoulos JD Wiggins CW Honick GL. Prevention of recurrences of myocardial infarction. Arch Intern Med 1964; 114: 348–358.

Enger E. Kontrollerte kliniske forsøk [Controlled Clinical Trials]. Oslo: Universitetsforlaget, 1966.

Otterstad JE Brosstad F. Utviklingen av den medisinske behandlingen av hjertepasienter [The development of the medical treatment of cardiac patients]. In: Forfang K Rasmussen K , ed. Det norske hjerte. Norsk hjertemedisinsk historie [The Norwegian Heart. Norwegian Cardiology History]. Oslo: Universitetsforlaget, 2007: 193–205.

Chalmers TC Matta RJ Smith H Kunzler A-M. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977; 297: 1091–1096.

Borchgrevink CF. Long-term anticoagulant therapy in angina pectoris and myocardial infarction. Acta Med Scand 1960; 359.

Pedersen T. Six-year follow-up of the Norwegian multicenter study on timolol after acute myocardial infarction N Engl J Med 1985; 313: 1055–1058.

Pedersen T Kjekshus J Berg K Haghfelt T . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.

Hurlen M Abdelnoor M Smith P Erikssen J Arnesen H. Warfarin, aspirin or both after myocardial infarction. N Engl J Med 2002; 347: 969–974.

Smith P Arnesen H Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147–152.

Bønaa KH Njølstad I Ueland PM Schirmer H Tverdal A Steigen T , et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578–1588.

International Anticoagulant Review Group. Collaborative analysis of long-term anticoagulant administration after acute myocardial infarction. Lancet 1970; 1: 203–209.

Loeliger EA. Oral anticoagulation in the secondary prevention of myocardial infarction. Acta Med Scand Suppl 1981; 651: 305–315.

Anand SS Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999; 282: 2058–2067.

Connors JM. Testing and monitoring direct oral anticoagulants. Blood 2018; 132: 2009–2015.

Hirsch J. Antithrombotic therapy. In: Kaushausky K and Berliner N, eds. 50 Years of Haematology. Research that Revolutionized Patient Care. Washington, DC: American Society of Hematology, 2008:28–31.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–360.

Baigent C Collins R Appleby P Parish S Sleight P Peto R. ISIS2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 1998; 316: 1337–1343.

OASIS (The Organization to Assess Strategies for Ischemic Syndromes Investigators). Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol 2001; 37: 475–484.

CURE (The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigation). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.

Eikelboom JW Connolly SJ Bosch J Dagenais GR Hart RG Shestakovska O. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319–1330.

Atar D Bode C Stuerzenbecher A Verheugt FWA. Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the last decade. Fund Clin Pharmacol 2014; 28: 353–363.

European Society of Cardiology Guidelines. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018; 39: 119–177.

European Society of Cardiology Guidelines. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289–1367.

Altiok E Marx N. Oral anticoagulation Dtsch Arztebl Int 2018; 115: 776–783.

Wadsworth D Sullivan E Jacky T Sprague T Feinman H Kim J. A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant. J Clin Pharm Ther 2021; 46: 560–570.

Abildgaard U Orning O (2002). Christopher Juel Bjerkelund. Aftenposten 16 July 2002: 15.